Bridgebio Pharma Stock Price, News & Analysis

BBOT announced the publication of preclinical data in Science for BBO-10203, a first-in-class oral inhibitor that blocks RAS-PI3Kα interaction in cancer treatment. The drug works by covalently binding to PI3Kα's RAS-binding domain, preventing interaction with H-, N-, and KRAS proteins. Notably, BBO-10203 demonstrated significant tumor growth inhibition across multiple cancer types without causing hyperglycemia, a common side effect. The compound showed enhanced efficacy when combined with other therapies like CDK4/6 inhibitors and HER2 inhibitors. Currently, BBO-10203 is being evaluated in the Phase 1 BREAKER-101 study for various cancers including HER2+ breast cancer, HR+/HER2- breast cancer, and KRAS mutant colorectal and non-small cell lung cancers.

BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will engage in a fireside chat session scheduled for Monday, June 9 at 8:40 am ET in Miami, FL. Investors and interested parties can access the live webcast through BridgeBio's investor relations website, with a replay available for 30 days following the event.

BridgeBio Pharma (NASDAQ: BBIO) presented promising data from the ATTRibute-CM study for acoramidis (marketed as Attruby/BEYONTTRA) in treating ATTR-CM. The drug showed a 43% reduction in cardiovascular hospitalizations due to atrial fibrillation and a 17% reduction in new-onset AF in patients without prior history. Key findings include: - 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations at Month 30 - 50% reduction in cumulative frequency of cardiovascular hospitalization events - 86.7-meter improvement in 6-minute walk distance for variant ATTR-CM patients - 20.3-point improvement in quality of life scores The drug is already approved by FDA, European Commission, Japanese PMDA, and UK MHRA. Results suggest acoramidis could be considered as a first-line treatment for ATTR-CM patients, particularly beneficial for those with the hereditary variant form (ATTRv-CM).

BridgeBio Pharma (NASDAQ: BBIO) published significant findings from its ATTRibute-CM Phase 3 trial of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The study revealed that for every 5-mg/dL increase in serum TTR levels within 28 days of treatment, mortality risk reduced by up to 31.6% through Month 30. The drug demonstrated rapid benefits, including a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations at Month 30, and a 50% reduction in cardiovascular hospitalization events. Treatment resulted in an early rise in serum TTR levels (mean 9.1 mg/dL) within 28 days, sustained throughout the 30-month period. Acoramidis is now approved as Attruby in the US and as BEYONTTRA in Europe, Japan, and the UK.

BridgeBio Pharma (BBIO) has granted equity awards to 36 new employees in the form of restricted stock units totaling 101,974 shares of common stock. The grants were approved by the compensation committee on May 9, 2025. The vesting schedule includes 25% of shares vesting on May 16, 2026, followed by quarterly vesting of the remaining shares in one-twelfth increments, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

BridgeBio Pharma (NASDAQ: BBIO) has initiated ACT-EARLY, the first-ever primary prevention study for ATTR amyloidosis, with the first participant receiving acoramidis. The study will enroll ~600 asymptomatic carriers of pathogenic TTR variants to evaluate if early intervention can prevent or delay disease onset. This follows significant results from the ATTRibute-CM Phase 3 trial, where acoramidis showed a 59.1% risk reduction in ATTRv-CM patients. The drug, approved as Attruby™ in the US and BEYONTTRA® in Europe, Japan, and the UK, is a near-complete TTR stabilizer. The primary endpoint will measure time to development of ATTR-CM and/or ATTR-PN, addressing a critical unmet need for at-risk individuals who currently have no preventative treatment options.

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025. The company will present multiple studies on acoramidis for treating transthyretin amyloid cardiomyopathy (ATTR-CM) from the ATTRibute-CM study. Key presentations include:

- Clinical outcomes and quality of life measures for acoramidis in variant ATTR-CM - Post-hoc analysis showing lower incidence of atrial fibrillation events - Data on serum TTR levels in both wild-type and variant ATTR-CM patients - Real-world disease progression studies - Analysis of ATTR-CM diagnosis timelines - Mortality cause analysis from the ATTRibute-CM study

The presentations feature research from leading medical institutions including University College London, Stanford University, and the University of Montreal.

BridgeBio Pharma (NASDAQ: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on Wednesday, May 14 at 2:20 PM PT in Las Vegas, NV.

Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will remain available for 30 days following the presentation.

BridgeBio Pharma reported strong Q1 2025 results, with $36.7 million in first-quarter U.S. Attruby net product revenue. The company has seen 2,072 unique patient prescriptions from 756 healthcare providers since FDA approval in November 2024.

Key highlights:

• Cash position of $540.6 million, with additional $105 million in milestone payments expected in Q2
• Total revenues of $116.6 million for Q1 2025
• Successful global expansion with BEYONTTRA approvals in EU, UK, and Japan
• Positive results in hypochondroplasia and hypoparathyroidism trials

The company's pipeline shows progress across multiple programs, including acoramidis for ATTR-CM, BBP-418 for LGMD2I/R9, and encaleret for ADH1. Notable achievements include a 42% reduction in all-cause mortality for Attruby and 78% success rate in encaleret's proof-of-principle study for hypoparathyroidism.